Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase EARLY_PHASE1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2768Triple Negative Breast Neoplasms 406Neoplasm Metastasis 156Breast Neoplasms, Male 102Neoplasms 100Ovarian Neoplasms 69Carcinoma, Non-Small-Cell Lung 68Carcinoma, Intraductal, Noninfiltrating 68Lung Neoplasms 66Brain Neoplasms 60Colorectal Neoplasms 52Inflammatory Breast Neoplasms 50Advanced Breast Cancer 49Breast Carcinoma In Situ 47Prostatic Neoplasms 42Melanoma 38Pancreatic Neoplasms 37Stomach Neoplasms 32Uterine Cervical Neoplasms 28Sarcoma 27HER2-positive Breast Cancer 27Endometrial Neoplasms 25Head and Neck Neoplasms 24Recurrence 23Colonic Neoplasms 22Carcinoma, Renal Cell 21Carcinoma, Ovarian Epithelial 21Small Cell Lung Carcinoma 20Multiple Myeloma 20Carcinoma, Ductal, Breast 20

Interventions

palbociclib 2Fulvestrant 2pyrotinib 1Trastuzumab 1Letrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Estrogen Receptor-positive Breast Cancer × Breast × Clear all
NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
93 enrolled 16 charts
Breast

Estrogen Receptor-positive Breast Cancer

NCT05076695 2021-10-13

NeoTPPF

Fudan University

Phase 2 Unknown
37 enrolled
Breast

Estrogen Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡